Corvus Pharmaceuticals, Inc. releases salary data. CEO sees compensation rise 8%

Corvus Pharmaceuticals, Inc. just filed its annual proxy statement, which details the salary information of its key executives. In 2018, the company's CEO made 1,362,313.

The table is included below:


























































































































































































































































































































































































Non‑equity





















































































Incentive













































Base




















Stock










Option










plan










All other

























Fiscal










salary




















awards










awards










compensation










compensation










Total





Name and principal position










year










($)










Bonus($)










($)










($)(1)










($)










($) (2)










($)





Richard A. Miller, M.D.










2018










302,961
































1,056,352





















3,000










1,362,313





President and Chief Executive Officer










2017










301,837
































948,765





















2,000










1,252,602





Leiv Lea










2018










321,121
































422,540





















3,000










746,661





Chief Financial Officer










2017










291,437
































303,605





















2,000










597,042





Joseph J. Buggy, Ph.D.










2018










143,568
































1,137,094
































1,280,662





Executive Vice President, Discovery Research


















































































The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Corvus Pharmaceuticals, Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

On September - Sept. 17, 2020
Corvus Pharmaceuticals, Inc. director was just granted 30,000 options - Sept. 15, 2020
Corvus Pharmaceuticals, Inc. director just declared 0 ownership of the company. - Sept. 15, 2020
Departure of Directors or Certain - Sept. 11, 2020
On September - Sept. 10, 2020

Auto Refresh

Feedback